This section contains two parts. The first part includes references to documents, related weblinks and existing toolkits regarding behavioural surveillance methodology and evaluation methods in the HIV/AIDS field.
In the context of the ongoing outbreak of Shiga toxin-producing E. coli (STEC) that affects by now citizens from 13 EU member states, it is crucial not only to align the efforts regarding investigation and control of the outbreak but also to share knowledge among practitioners across Europe on the patho-physiological and clinical characteristics of infection caused by this unusual epidemic strain, and review patient management options.
On 9 June, ECDC will be hosting a technical side-event to the United Nations High-Level Meeting on AIDS 2011. The event will highlight how countries and regions with differing epidemiology could improve their responses to HIV/AIDS.
Today, the German authorities published a press release on the current Shiga toxin-producing E.coli outbreak. In their joint statement they recommended in particular to abstain from eating raw sprouts.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
The overall objective is to improve early detection and response to outbreak of zoonotic diseases at the EU level through strengthened collaboration with the animal health sector and other agencies and organizations working at the animal-human interface.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.